Therapeutic regimens for multiple myeloma (MM) that use a combination of the anti-CD38 monoclonal antibody daratumumab induce higher rates of sustained minimal residual disease
Therapeutic regimens for multiple myeloma (MM) that use a combination of the anti-CD38 monoclonal antibody daratumumab induce higher rates of sustained minimal residual disease
Therapeutic regimens for multiple myeloma (MM) that use a combination of the anti-CD38 monoclonal antibody daratumumab induce higher rates of sustained minimal residual disease (MRD) negativity compared with standard care, according to results from two clinical trials.